Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.21.1
ACCRUED EXPENSES
3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

 

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    March 31, 2021     December 31, 2020  
             
Accrued clinical operations and trials costs   $ 11,956,892     $ 14,132,842  
Accrued product development costs     764,211       2,189,047  
Accrued compensation     3,746,283       4,222,594  
Accrued other     1,275,088       1,460,949  
Total   $ 17,742,474     $ 22,005,432